TENAYA THERAPEUTICS INC (TNYA)

Company Profile

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 141 full-time employees. The company went IPO on 2021-07-30. The firm is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The firm is advancing a pipeline of disease-modifying therapies that includes both gene therapies and small molecules discovered internally and developed using its product platforms and core capabilities to target defined sub-populations of patients with rare or prevalent forms of heart disease. Its product platforms include Gene Therapy, Cellular Regeneration and Precision Medicine to discover novel therapies for various forms of heart disease. The firm's lead product candidates include, TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy, TN-301, a small molecule for heart failure with preserved ejection fraction, and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

Company Info

TENAYA THERAPEUTICS INC

171 Oyster Point Blvd., Suite 500

South San Francisco CALIFORNIA

P: 14158652066

CEO: Faraz Ali

Employees: 141

Website: https://www.tenayatherapeutics.com/